West Nile Virus envelope (E) protein antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-West Nile Virus envelope (E) protein antibodies pairs and antigen for animal health (animal Cat/Feline, Dog/Canine, Equine/Horse, Avian/Bird/Poultry infectious disease West Nile fever) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Multiple species disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P244-Tg001-Ag01	Recombinant West Nile Virus envelope (E) protein protein	$3090.00
GMP-VT-P244-Tg001-Ab01	Anti-West Nile Virus envelope (E) protein mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P244-Tg001-Ab02	Anti-West Nile Virus envelope (E) protein mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P244-Tg001-Ab03	Anti-West Nile Virus envelope (E) protein human monoclonal antibody (mAb)	$3090.00
GMP-VT-P244-Tg001-Ab04	Anti-West Nile Virus envelope (E) protein human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P244-Tg001-Ag01
Product Name	Recombinant West Nile Virus envelope (E) protein protein
Pathogen	West Nile Virus
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-West Nile Virus envelope (E) protein antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in West Nile Virus level test of animal Cat/Feline, Dog/Canine, Equine/Horse, Avian/Bird/Poultry infectious disease with West Nile fever.
Tag	His
Product description	Recombinant West Nile Virus envelope (E) protein proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P244-Tg001-Ab01,GMP-VT-P244-Tg001-Ab02
Pathogen	West Nile Virus
Product Name	Anti-West Nile Virus envelope (E) protein mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant West Nile Virus envelope (E) protein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-West Nile Virus antibodies in West Nile Virus level test of animal Cat/Feline, Dog/Canine, Equine/Horse, Avian/Bird/Poultry infectious disease with West Nile fever.
Product description	Anti-West Nile Virus envelope (E) protein mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-West Nile Virus antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P244-Tg001-Ab03,GMP-VT-P244-Tg001-Ab04
Pathogen	West Nile Virus
Product Name	Anti-West Nile Virus envelope (E) protein human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant West Nile Virus envelope (E) protein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-West Nile Virus antibodies in West Nile Virus level test of animal Cat/Feline, Dog/Canine, Equine/Horse, Avian/Bird/Poultry infectious disease with West Nile fever.
Product description	Anti-West Nile Virus envelope (E) protein mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

The West Nile Virus (WNV) is a pathogenic arbovirus that has been responsible for several outbreaks in humans and animals around the world. The virus was first discovered in Uganda in 1937, and since then, it has spread to many countries, including those in Europe, Africa, Asia, and North America. In humans, WNV infection can cause severe neurological disease, such as meningitis or encephalitis, and even death.

WNV is an enveloped RNA virus with a positive-sense single-stranded genome of approximately 11 kb. The genome encodes for three structural proteins, including capsid (C), premembrane/membrane (prM/M), and envelope (E), and seven nonstructural proteins, including NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. The E protein is essential for viral entry into host cells, and its function is conserved among flaviviruses. The virus's genome structure and essential proteins make it a primary target for antiviral drugs and vaccine development.

WNV transmission occurs primarily through mosquito bites. Infected mosquitoes acquire the virus by feeding on infected birds, which serve as the primary reservoir host. Once the mosquitoes are infected, they can transmit the virus to other animals or humans through subsequent bites. Additionally, WNV can be transmitted through blood transfusions, organ transplants, and vertical transmission (from mother to fetus).

WNV infections in humans range from asymptomatic to severe, with less than 1% of infected individuals developing severe disease. The incubation period in humans ranges from 2-14 days after infection. Most cases of WNV infection are asymptomatic or present as a mild, flu-like illness that resolves without treatment. However, in severe cases, the virus can invade the central nervous system and cause meningitis, encephalitis, or acute flaccid paralysis. Additionally, neurological symptoms of severe disease can include seizures, confusion, muscle weakness, and loss of consciousness.

There is no specific antiviral treatment for WNV infection, and management involves supportive care to alleviate symptoms. However, several vaccines are under development to prevent WNV infection in humans. The current WNV vaccine available for horses has shown efficacy in preventing disease in vaccinated animals.

Diagnosis of WNV infection involves various methods, including nucleic acid testing, serology, and viral isolation. Nucleic acid testing targets specific regions of the viral genome, such as the NS5 or E gene, and is useful for detecting the virus in blood, cerebrospinal fluid, or tissues. Serological tests detect antibodies against the virus in blood samples and can differentiate between recent and past infections. Viral isolation involves culturing the virus from patient specimens, such as blood or cerebrospinal fluid.

In conclusion, WNV is a significant public health concern that poses a severe risk to human and animal health. Understanding the virus's biology and pathogenesis is crucial for developing effective preventive and therapeutic strategies. The availability of accurate diagnostic approaches can aid in early intervention and management of severe cases. Ongoing research efforts are necessary to advance WNV knowledge and reduce the burden of its associated diseases.

About GDU